Sildenafil in the treatment of pulmonary hypertension

Abstract

The paper describes the clinical use of a phosphodiesterase 5 inhibitor (sildenafll) in a patient with primary pulmonary hypertension during a long-term controlled follow-up. The 6-year use of sildenafll as monotherapy for pulmonary hypertension had a significant positive effect as a decrease in the functional class of pulmonary hypertension from 3 to 1, an increase in exercise tolerance, improvements in echocardiographic parameters and biochemical markers (brain natriuretic peptide), and a rise in oxygen uptake during cardiorespiratory testing.